VIKING THERAPEUTICS ($VKTX) posted quarterly earnings results on Wednesday, April 23rd. The company reported earnings of -$0.41 per share, missing estimates of -$0.33 by $0.08. The company also reported revenue of $0, equaling estimates of $0 by $0.
You can see Quiver Quantitative's $VKTX stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
VIKING THERAPEUTICS Insider Trading Activity
VIKING THERAPEUTICS insiders have traded $VKTX stock on the open market 18 times in the past 6 months. Of those trades, 1 have been purchases and 17 have been sales.
Here’s a breakdown of recent trading of $VKTX stock by insiders over the last 6 months:
- GREG ZANTE (Chief Financial Officer) has made 0 purchases and 10 sales selling 181,996 shares for an estimated $12,239,758.
- BRIAN LIAN (President & CEO) has made 0 purchases and 2 sales selling 194,490 shares for an estimated $8,313,601.
- MARIANNA MANCINI (Chief Operating Officer) has made 0 purchases and 2 sales selling 54,215 shares for an estimated $2,317,599.
- J MATTHEW SINGLETON sold 16,000 shares for an estimated $1,272,000
- SARAH KATHRYN ROUAN has made 1 purchase buying 1,240 shares for an estimated $29,942 and 1 sale selling 11,000 shares for an estimated $889,790.
- LAWSON MACARTNEY sold 2,000 shares for an estimated $137,333
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
VIKING THERAPEUTICS Hedge Fund Activity
We have seen 204 institutional investors add shares of VIKING THERAPEUTICS stock to their portfolio, and 215 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- PERPETUAL LTD removed 1,269,152 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $51,070,676
- MASSACHUSETTS FINANCIAL SERVICES CO /MA/ added 1,108,972 shares (+446.7%) to their portfolio in Q4 2024, for an estimated $44,625,033
- NORGES BANK added 1,096,559 shares (+601.3%) to their portfolio in Q4 2024, for an estimated $44,125,534
- AMERIPRISE FINANCIAL INC added 1,029,125 shares (+228.5%) to their portfolio in Q4 2024, for an estimated $41,411,990
- WESTFIELD CAPITAL MANAGEMENT CO LP removed 930,370 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $37,438,088
- BALYASNY ASSET MANAGEMENT L.P. added 860,449 shares (+inf%) to their portfolio in Q4 2024, for an estimated $34,624,467
- HOOD RIVER CAPITAL MANAGEMENT LLC removed 772,148 shares (-94.7%) from their portfolio in Q4 2024, for an estimated $31,071,235
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
VIKING THERAPEUTICS Analyst Ratings
Wall Street analysts have issued reports on $VKTX in the last several months. We have seen 5 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- BTIG issued a "Buy" rating on 04/14/2025
- Morgan Stanley issued a "Overweight" rating on 03/12/2025
- Piper Sandler issued a "Overweight" rating on 12/02/2024
- Laidlaw issued a "Buy" rating on 11/04/2024
- Jefferies issued a "Buy" rating on 11/04/2024
To track analyst ratings and price targets for VIKING THERAPEUTICS, check out Quiver Quantitative's $VKTX forecast page.
VIKING THERAPEUTICS Price Targets
Multiple analysts have issued price targets for $VKTX recently. We have seen 3 analysts offer price targets for $VKTX in the last 6 months, with a median target of $110.0.
Here are some recent targets:
- Biren Amin from Piper Sandler set a target price of $74.0 on 12/02/2024
- Yale Jen from Laidlaw set a target price of $110.0 on 11/04/2024
- Roger Song from Jefferies set a target price of $110.0 on 11/04/2024
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
